SCHEMBL17847696

SCHEMBL17847696

O=C(Cc1ccc(-c2ccc(F)cc2)cc1)Oc1ccc(F)c(F)c1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
ASAH1 Q13510 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
MAOB P27338 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KLK7 P49862 2/20 0.40
CA2 P00918 2/20 0.40
CA5A P35218 2/20 0.40
ATM Q13315 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAOA P21397 1/20 0.40
SENP1 Q9P0U3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19806732 0.87 KMT2A (0.53) KMT2AASAH1SMN1; SMN2MAOBL3MBTL1
SCHEMBL19651377 0.83 KMT2A (0.57) KMT2AASAH1SMN1; SMN2L3MBTL1NPC1
SCHEMBL4770316 0.82 KMT2A (0.78) KMT2AASAH1SMN1; SMN2L3MBTL1NPC1
SCHEMBL6937444 0.78 KMT2A (0.68) KMT2ASMN1; SMN2MEN1L3MBTL1KLK7
SCHEMBL17971120 0.78 APP (0.40) KMT2ASMN1; SMN2MEN1CA2
SCHEMBL17857804 0.77 KMT2A (0.58) KMT2AASAH1SMN1; SMN2MAOBMAOA
SCHEMBL15763945 0.76 KMT2A (0.42) KMT2ASMN1; SMN2MEN1MAOBL3MBTL1
SCHEMBL18118880 0.75 KMT2A (0.41) KMT2AASAH1SMN1; SMN2MEN1L3MBTL1
SCHEMBL31225539 0.75 KMT2A (0.51) KMT2ASMN1; SMN2MEN1RAB9AKLK7
SCHEMBL19599396 0.75 KMT2A (0.59) KMT2AASAH1SMN1; SMN2MAOBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3234067-B1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2018-08-22 EP disclosed
US-20180022996-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2018-01-25 US disclosed
US-20180022996-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2018-01-25 US disclosed
US-20180022996-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2018-01-25 US disclosed
US-20170369784-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2017-12-28 US disclosed
EP-3234067-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA Merck Patent GmbH (DE) 2017-10-25 EP disclosed
WO-2016107664-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2016-07-07 WO disclosed
WO-2016096082-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2016-06-23 WO disclosed
WO-2016096081-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2016-06-23 WO disclosed
WO-2016096082-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369784-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MTX1, S100A11, MCRS1 KMT2A 3390/4885ASAH1 4725/4885SMN1; SMN2 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.